North America Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type (Adults and Geriatric), End User (Hospitals, Specialty Clinics, Home Healthcare Settings, Ophthalmology Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico.) – Industry Trends and Forecast to 2028.
Market Analysis and Insights : North America Ocular Pain Market
The North America ocular pain market is expected to grow in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.7% in the forecast period of 2021 to 2028 and is expected to reach USD 699.19 million by 2028. Increasing unhygienic and sedentary lifestyle acts as a driver for the North America ocular pain market growth.
Ocular pain also, known as eye pain, commonly occurs due to mild irritation, but it is rarely a symptom of a serious condition. Mostly the pain resolves without medicine or further treatment, and it recovers by the self-immune system. However, ocular pain with underlying primary ophthalmic disorders requires timely treatment. Eye pains are generally categorized under two categories, such as ocular pain, which occurs over the eye's surface, creating sensations of scratching, burning, or itching. They are caused due to a person’s eyelashes, foreign objects, infection, or trauma. Often ocular pain is treated with eye drops and topical steroids or NSAIDs. Ocular pain occurs with underlying primary eye diseases like conjunctivitis, contact lens irritation, corneal abrasion, injury, blepharitis, and sty. The other advanced treatments, like stimulation therapies, are also used for severe neuro ocular pain, appropriately diagnosed.
Increasing unhygienic and sedentary lifestyles, rising prevalence of ophthalmic disorders, and ocular pain act as drivers for the North America ocular pain market. The increasing awareness among people for eye-related diseases and growing cases of ocular migraine is further boosting the market growth. The side effects of eye treatment medicines and the high cost of eye treatment and medication are restraining the North America ocular pain market growth. Increasing research and development activities, rising healthcare expenditure and disposable income, and growing geriatric population acts as opportunities for the North America ocular pain market. Lack of healthcare facilities for eye treatment and stringent regulatory framework poses a challenge for the North America ocular pain market growth.
North America ocular pain market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the ocular pain market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
North America Ocular Pain Market Scope and Market Size
North America ocular pain market is segmented on the basis of the disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the North America ocular pain market is segmented into ocular pain with eye diseases and ocular pain without primary eye diseases. In 2021, the ocular pain with eye diseases segment is expected to dominate the North America ocular pain market as ocular pain is the initial symptom of most eye diseases.
- On the basis of type, the North America ocular pain market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to raising funds for research activities over diagnostic ophthalmology.
- On the basis of application, the North America ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. In 2021, the glaucoma segment is expected to dominate dominating the market due to less awareness during the initial stages of pain.
- On the basis of route of administration, the North America ocular pain market is segmented into topical, periocular, intraocular, oral, and others. In 2021, the topical segment is expected to dominate dominating the market as enormous topical solutions and products are implemented for ocular care.
- On the basis of drug type, the North America ocular pain market is segmented into prescription and over the counter. In 2021, the prescription segment is expected to dominate dominating the market due to rising government regulations and guidelines for OTC drugs, and hence prescription is mandated.
- On the basis of population type, the North America ocular pain market is segmented into adults and geriatric. In 2021, the adults segment is expected to dominate dominating the market due to their rising sedentary lifestyle and habits.
- On the basis of end user, the North America ocular pain market is segmented into hospitals, specialty clinics, home healthcare, ophthalmology centers, ambulatory surgical centers, and others. In 2021, the hospitals segment is expected to dominate dominating the market as there are increasing hospitals in developed countries of North America due to high economic growth.
- On the basis of distribution channel, the North America ocular pain market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment is expected to dominate the market as they provide quality products.
North America Ocular Pain Market Country Level Analysis
North America ocular pain market is analyzed, and market size information is provided by the country, disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel as referenced above.
The countries covered in the North America ocular pain market report are the U.S., Canada, and Mexico.
The diagnosis segment in the U.S of North American region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing cases of ophthalmic disorders. The diagnosis segment in Canada is the second dominating market in North America owing to the increasing unhygienic habits of people. Mexico is the third leading market in this region, and the diagnosis segment dominates in this country due to the rising number of market players and initiatives.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Ocular Pain Treatment is Boosting the Market Growth of the North America Ocular Pain Market
The North America ocular pain market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and North America Ocular Pain Market Share Analysis
The North America ocular pain market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America ocular pain market.
The major companies dealing in the North America ocular pain market are Johnson & Johnson Services, Inc., Pfizer Inc., EyePoint Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd, Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., Kala Pharmaceuticals, Novartis AG, Omeros Corporation, Allergan (An AbbVie Company), SiteOne Therapeutics, Inc., OKYO Pharma Limited, Fera Pharmaceuticals, Vyluma, TALLC Inc., IACTA Pharmaceuticals, Inc., Allakos Inc., Aldeyra Therapeutics, Inc., Novaliq GmbH, and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts and agreements are also initiated by companies worldwide, which accelerate the North America ocular pain market.
For instance,
- In November 2020, Allakos Inc. participated in the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting. The company presented its product over Eosinophilic Gastrointestinal Diseases and other diseases to attended customers. This strengthened their position in the market
- In October 2020, Aldeyra Therapeutics, Inc. presented their Reproxalap ophthalmic solution’s (0.25% and 0.5%) clinical data, which surpassed phase 2. They also demonstrated their application over allergic conjunctivitis. This strengthened their position in a focused market
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player enhance the company's footprints in the ocular pain market, which also benefits the organization’s profit growth.
SKU-